10 recruiting, 2 active not recruiting, 1 suspended, 1 terminated. 9 Phase 1, 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 9 | Recruiting 8, Suspended 1 |
| Phase 2 | 7 | Recruiting 4, Active not recruiting 2, Terminated 1 |
Follow ZEN-3694: new trials by email Literature Review of ZEN-3694 trials Research Report on ZEN-3694
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The COSMYC Trial (COmbined Suppression of MYC) ZEN-3694, Testosterone cypionate, Enzalutamide - Metastatic Castration-resistant Prostate Cancer | Phase 2 | Recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 50 | 2025-08-19 | 2026-06-18 |
| Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer BET Bromodomain Inhibitor ZEN-3694, Biopsy Procedure, Biospecimen Collection - Metastatic Colorectal Adenocarcinoma, Recurrent Colorectal Adenocarcinoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 30 | 2024-06-05 | 2026-09-23 |
| Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer BET Bromodomain Inhibitor ZEN-3694, Biopsy Procedure, Biospecimen Collection - Recurrent Endometrial Carcinoma, Recurrent Endometrial Clear Cell Adenocarcinoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 65 | 2023-12-18 | 2026-10-21 |
| Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers BET Bromodomain Inhibitor ZEN-3694, Biopsy Procedure, Biospecimen Collection - Metastatic Colorectal Carcinoma, Metastatic Malignant Solid Neoplasm | Phase 1 | Recruiting | National Cancer Institute (NCI) | 30 | 2023-11-08 | 2026-09-29 |
| Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors Abemaciclib, BET Bromodomain Inhibitor ZEN-3694, Biopsy Procedure - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 1 | Recruiting | National Cancer Institute (NCI) | 45 | 2023-08-10 | 2026-07-31 |
| Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer BET Bromodomain Inhibitor ZEN-3694, Biopsy Procedure, Biospecimen Collection - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 1 | Recruiting | National Cancer Institute (NCI) | 57 | 2023-05-18 | 2026-09-30 |
| Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors BET Bromodomain Inhibitor ZEN-3694, Computed Tomography, Core Biopsy - Advanced Malignant Solid Neoplasm, Locally Advanced Pancreatic Carcinoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 49 | 2022-11-16 | 2026-07-15 |
| Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial BET Bromodomain Inhibitor ZEN-3694, Biopsy Procedure, Biospecimen Collection - Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 88 | 2022-11-14 | 2026-09-25 |
| Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer BET Bromodomain Inhibitor ZEN-3694, Binimetinib, Biopsy Procedure - Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm | Phase 1 | Recruiting | National Cancer Institute (NCI) | 42 | 2022-08-02 | 2026-10-14 |
| Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Cisplatin and Etoposide or Carboplatin and Paclitaxel) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma BET Bromodomain Inhibitor ZEN-3694, Biopsy Procedure, Biospecimen Collection - Advanced NUT Carcinoma, Metastatic NUT Carcinoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 36 | 2022-07-13 | 2026-07-31 |
| Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors BET Bromodomain Inhibitor ZEN-3694, Biopsy Procedure, Biospecimen Collection - Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm | Phase 1 | Suspended | National Cancer Institute (NCI) | 66 | 2022-02-02 | 2026-08-17 |
| ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer ZEN003694, Enzalutamide - Metastatic Castration-Resistant Prostate Cancer | Phase 2 | Recruiting | Zenith Epigenetics | 200 | 2021-09-08 | 2026-05-08 |
| ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer BET Bromodomain Inhibitor ZEN-3694, Enzalutamide, Pembrolizumab - Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma | Phase 2 | Active not recruiting | Rahul Aggarwal | 61 | 2021-01-26 | 2026-07-23 |
| A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast Cancer ZEN003694, Talazoparib - Triple Negative Breast Cancer | Phase 2 | Terminated | Zenith Epigenetics | 115 | 2019-06-26 | 2025-10-07 |
Neoplasm Metastasis (5) · Triple Negative Breast Neoplasms (3) · Breast Neoplasms (2) · Colorectal Neoplasms (2) · Prostatic Neoplasms (2) · Endometrial Neoplasms (1) · Ovarian Neoplasms (1) · Pancreatic Neoplasms (1)
National Cancer Institute (NCI) (10) · Zenith Epigenetics (2) · Rahul Aggarwal (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1)
United States (14) · China (2) · Belgium (1) · Spain (1)
Jia Luo (2) · Ana C Garrido-Castro (1) · Anwaar Saeed (1) · Fiona Simpkins (1) · Haider S Mahdi (1) · Patricia M LoRusso (1) · Rahul R Aggarwal, MD (1) · Salvador Alonso Martinez (1) · Samuel Denmeade, MD (1) · Sarina A Piha-Paul (1) · Timothy A Yap (1)
PMID 34385584, PMID 38497709, PMID 38501690, PMID 39863139, PMID 40611889, PMID 42101296
UM1CA186688 (3), UM1CA186709 (3), UM1CA186690 (2), 2018 (1), P50CA272391 (1), U10CA180868 (1), UM1CA186689 (1)